Shots:
- In this episode of the CXO Talks podcast, PharmaShots speaks with Rick Modi, CEO at Affinia Therapeutics
- Driven by cutting-edge innovation, Affinia is pioneering and re-imagining adeno-associated virus serotype 9 (AAV9), a gene therapy delivery method for conditions affecting cardiac muscle, skeletal muscle, and the central nervous system
- Rick articulates the diagnostic and therapeutic gaps for the BAG3 dilated cardiomyopathy and talks at great length about Affinia’s lead candidate AFTX-201. Watch the full podcast by clicking the link below
About the Author:
Rick Modi
CEO at Affinia Therapeutics
Rick has helped bring transformative medicines to patients in more than 10 therapeutic areas at multiple successful biotech companies. Before joining Affinia Therapeutics, Rick was chief business officer at AveXis, where he played a significant role in the launch of Zolgensma® (onasemnogene abeparvovec-xioi), the company’s flagship gene therapy product, and the company’s build and sale to Novartis for $8.7 billion. Prior to AveXis, Rick was chief business officer at Catabasis Pharmaceuticals and senior vice president in the commercial group at InterMune until its acquisition by Roche.
Related Post: CXO Talks: Thomas Chalberg & Annahita Keravala from Genascence in a Candid Conversation with PharmaShots
